Preparation of Glycoconjugate Vaccines

Carbohydrate-Based Vaccines and Immunotherapies

Volumn , Issue , 2008, Pages 55-88

  Zou, Wei ^a   Jennings, Harold J ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Capsular polysaccharide protein conjugates; Glycoconjugate vaccine preparation; Lipopolysaccharide (LPS) and lipooligosaccharide (LOS) conjugates

Indexed keywords

EID: 84884209735     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470473283.ch2     Document Type: Chapter

References (123)

1. Gotschlich EC, Liu TY, Artenstein MS (1969) Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides. J. Exp. Med. 129:1349-1365.
2. Goldschneider I, Gotschlich EC, Artenstein MS (1969) Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129:1307-1326.
3. Gotschlich EC, Goldschneider I, Lepow ML, Gold R (1977) The immune responses to bacterial polysaccharides in man. In Haber E, Krause RM, Eds. Antibodies in Human Diagnosis and Therapy. Raven, New York, pp. 391-402.
4. Peltola H, Häyhty H, Sivonen A, Mäkelä PH (1977) Haemophilus influenzae type b capsular polysaccharide vaccine in children: A double blind field study of 100,000 vaccine in children 3 months to 5 years of age in Finland. Pediatrics 60:730-737.
5. Goebel WF, Avery OT (1931) Chemo-immunological studies on conjugated carbohydrate-proteins. IV. The synthesis of p-aminobenzyl ether of the soluble specific substance of type III pneumococcus and its coupling with protein. J. Exp. Med. 54:431-436.
6. Avery OT, Goebel WF (1931) Chemo-immunological studies on conjugated carbohydrate-proteins: V. The immunological specifity of an antigen prepared by combining the capsular polysaccharide of type III pneumococcus with foreign protein. J. Exp. Med. 54:437-447.
7. Goebel WF (1940) Study on antibacterial immunity induced by artificial antigens. II. Immunity to experimental pneumococcal infection with antigens containing saccharides of synthetic origin. J. Exp. Med. 72:33-48.
8. Jennings HJ (1983) Capsular polysaccharides as human vaccines. Adv. Carbohy. Chem. Biochem. 41:155-208.
9. Robbins JB, Schneerson R (1990) Polysaccharide protein conjugates: A new generation of vaccines. J. Infect. Dis. 161:821-832.
10. Jennings HJ, Sood RK (1994) Synthetic glycoconjugates as human vaccines. In Lee YC, Lee RT, (Eds) Neoglycoconjugates. Preparation and Applications. Academic, London, pp. 325-371.
11. Pozsgay V (2001) Oligosaccharide-protein conjugates as vaccine candidates against bacteria. Adv. Carbohy. Chem. Biochem. 56:153-199.
12. Anderson PW, Pichichero ME, Insel RA, Betts R, Eby R, Smith DH (1986) Vaccines consisting of periodate-cleaved oligosaccharides from the capsule of Haemophilus influenzae type b coupled to a protein carrier: Structural and temporal requirements for priming in the human infant. J. Immunol. 137:1181-1186.
13. Anderson PW (1983) Immunogenic conjugates. U.S. Patent 4,673574.
14. Jennings HJ, Lugowski C (1981) Immunochemistry of group A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J. Immunol. 127:1011-1018.
15. Schneerson R, Barrera O, Sutton A, Robbins JB (1980) Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J. Exp. Med. 152:361-376.
16. Gordon LK (1985) Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine. U.S. Patent 4,496,538.
17. Gordon LK (1987) Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine. U.S. Patent 4,644,059.
18. Claesson BA, Schneerson R, Trollfors B, Lagergard T, Taranger J, Robbins JB (1990) Duration of serum antibodies elicited by Haemophilus influenzae type b capsular polysaccharide alone or conjugated to tetanus toxoid in 18-to 23-month-old children. J. Pediat. 116:929-931.
19. Axen R, Porath J, Ernback S (1967) Chemical coupling of peptides and proteins to polysaccharides by means of cyanogen halides. Nature 214:1302-1304.
20. Porath J (1974) General methods and coupling procedures. In Jokoby WB, Wilchek M, (Eds) Methods in Enzymology. Academic, New York, pp. 13-30.
21. Parikh I, Martin S, Cuatrecasas P (1974) Topics in the methodology of substitution reaction. In Jokoby WB, Wilchek M,, Eds. Methods in Enzymology, Academic, New York, pp. 77-102.
22. Wilchek M, Miron T, Kohn J (1984) Affinity chromatography. In Jokoby WB,, Ed. Methods in Enzymology, Academic, New York, pp. 3-55.
23. Kagedal L, Akisanya A (1971) Binding of covalent proteins to polysaccharides bycyanogen bromide and organic cyanates. Preparation of soluble glycine-, insulin-and ampicillin-dextran. Acta Paediatr Jpn. 25:1855-1859.
24. Chu CY, Schneerson R, Robbins JB, Rastogi SC (1983) Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharideprotein conjugates. Infect. Immun. 40:245-256.
25. Hilleman MR, Tai JY, Tolman RL, Vella PP (1984) Coupled H. influenzae type b vaccine. U.S. Patent 4,459286.
26. Marburg S, Jorn D, Tolman RL, Arison B, McCauley J, Kniskern PJ, Hagopian A, Vella PP (1986) Bimolecular chemistry of macromolecules: Synthesis of bacterial polysaccharide conjugates with Neisseria meningitidis membrane protein. J. Am. Chem. Soc. 108:5282-5287.
27. Marburg S, Tolman RL, Kniskern PJ (1987) Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency. U.S. Patent 4,695624.
28. Marburg S, Tolman RL, Kniskern PJ, Miller WJ, Hagopian A, Ip CC, Hennessey Jr JP, Kubek DJ, Burke PD (1997) Pneumococcal polysaccharide conjugate vaccine. U.S. Patent 5,623057.
29. Schlesinger Y, Granoff DM (1992) Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. J. Am. Med. Assoc. 267:1489-1494.
30. Anderson PW, Pichichero ME, Stein EC, Porcelli S, Betts RFCDM, Korones D, Insel RA, Zahradnik JM, Eby R (1989) Effect of oligosaccharide chain length, exposed terminal group, and hapten loading on the antibody response of human adults and infants to vaccines consisting of Haemophilus influenzae type b capsular antigen unterminally coupled to the diphtheria protein CRM197. J. Immunol. 142:2464-2468.
31. Sniadack DH, Schwartz B, Lipman H, Bogaerts J, Butler JC, Dagan R, Echaniz-Avilas G, Lloyd-Evans N, Fenoll A, Girgis NI, Henrichsen J, Klugman K, Lehmann D, Takala AK, Vandepitte J, Gove S, Breiman RF (1995) Potential interventions for the prevention of childhood pneumonia: Geographic and temporal differences in serotype and serogroup distribution of invasive pneumococcal isolates from children-Implications for vaccine strategies. Pediat. Infect. Dis. J. 14:503-510.
32. Dagan R, Kayhty H, Wuorimaa T, Yaich M, Bailleux F, Zamir O, Eskola J (2004) Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants. Pediat. Infect. Dis. J. 23:91-98.
33. Dagan R, Goldblatt D, Maleckar JR, Yaich M, Eskola J (2004) Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular Pertussis components. Infect. Immun. 72:5383-5391.
34. Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, Kohl I, Lommel P, Prieels J-P, Schuerman L (2006) Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: A randomised double-blind efficacy study. Lancet 367:740-748.
35. Maiden MC, Stuard JM (2002) Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 359:1829-1830.
36. Jessouroun E, Da Silveira IAF, Bastos RC, Frasch CE, Lee JC (2004) Process for preparing polysaccharide-protein vaccines. Patent PCT/US2004/026431 (WO/2005/037320).
37. Richmond P, Borrow R, Goldblatt D, Findlow J, Martin S, Morris R, Cartwright K, Miller E (2001) Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J. Infect. Dis. 183:160-163.
38. Costantino P, Viti S, Podda A, Velmonte MA, Nencioni L, Rappuoli R (1992) Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 10:691-698.
39. Bilukha OO, Rosenstein N (2005) Prevention and control of meningococcal disease: Recommendations of the Advisory Committee on Immunization Practice (ACIP). MMWR 54(RR-7):1-21.
40. Jennings HJ, Roy R, Gamian A (1986) Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J. Immunol. 137:1708-1713.
41. Pon RA, Lussier M, Yang QL, Jennings HJ (1997) N-Propionylated group B meningococcal polysaccharide mimics a unique bactericidal capsular epitope in group B Neisseria meningitidis. J. Exp. Med. 185:1929-1938.
42. Jennings HJ (2003) Polysialic acid vaccines. In Wong CH, Ed. Carbohydrate-Based Drug Discovery, Vol. 1. Wiley-VCH, Weinheim, pp. 357-380.
43. Fusco PC, Michon F, Tai JY, Blake MS (1997) Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates. J. Infect. Dis. 175:364-372.
44. Bruge J, Bouveret LC, Danve B, Rougon G, Schulz D (2004) Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine 22:1087-1096.
45. Szu SC, Stone AL, Robbins JD, Schneerson R, Robbins JB (1987) Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals. J. Exp. Med. 166:1510-1524.
46. Szu SC, Li XR, Schneerson R, Vickers JH, Bryla D, Robbins JB (1989) Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high-or lower-molecular-weight Vi. Infect. Immun. 57:3823-3827.
47. Kossaczka Z, Bystricky S, Bryla DA, Shiloach J, Robbins JB, Szu SC (1997) Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker. Infect. Immun. 65:2088-2093.
48. Kossaczka Z, Lin F-YC, Ho VA, Thuy NTT, Bay PV, Thanh TC, Khiem HB, Trach DD, Karpas A, Hunt S, Bryla DA, Schneerson R, Robbins JB, Szu SC (1999) Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2-to 4-year-old children in Vietnam. Infect. Immun. 67:5806-5810.
49. Lewis AL, Nizet V, Varki A (2004) Discovery and characterization of sialic acid O-acetylation in group B Streptococcus. Proc. Natl. Acad. Sci. U.S.A. 101:11123-11128.
50. Michon F, Brisson JR, Dell A, Kasper DL, Jennings HJ (1988) Multiantennary groupspecific polysaccharide of group B streptococcus. Biochemistry 27:5341-5351.
51. Jennings HJ, Lugowski C, Kasper DL (1981) Conformational aspects critical to the immunospecificity of the type III group B streptococcal polysaccharide. Biochemistry 20:4511-4518.
52. Zou W, Mackenzie R, Therien L, Hirama T, Yang QL, Gidney MAJ, Jennings HJ (1999) Conformational epitope of the type III group B Streptococcus capsular polysaccharide. J. Immunol. 163:820-825.
53. Wessels MR, Paoletti LC, Rodewald AK, Michon F, DiFabio J, Jennings HJ, Kasper DL (1993) Stimulation of protective antibodies against type Ia and Ib group B Streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine. Infect. Immun. 61:4760-4766.
54. Wessels MR, Paoletti LC, Guttormsen HK, Michon F, D'Ambra AJ, Kasper DL (1998) Structural properties of group B streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy. Infect. Immun. 66:2186-2192.
55. Baker CJ, Paoletti LC, Wessels MR, Guttormsen HK, Rench MA, Hickman ME, Kasper DL (1999) Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J. Infect. Dis. 179:142-150.
56. Wessels MR, Paoletti LC, Kasper DL, DiFabio J, Michon F, Holme K, Jennings HJ (1990) Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J. Clin. Invest. 86:1428-1433.
57. Paoletti LC,Wessels MR, Michon F, DiFabio J, Jennings HJ, Kasper DL (1992) Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine. Infect. Immun. 60:4009-4014.
58. Kasper DL, Paoletti LC,Wessels MR, Guttormsen HK, Carey VJ, Jennings HJ, Baker CJ (1996) Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J. Clin. Invest. 98:2308-2314.
59. Baker CJ, Paoletti LC, Rench MA, Guttormsen HK, Carey VJ, Hickman ME, Kasper DL (2000) Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women. J. Infect. Dis. 182:1129-1138.
60. Baker CJ, Rench MA, Fernandez M, Paoletti LC, Kasper DL, Edwards MS (2003) Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. J. Infect. Dis. 188:66-73.
61. Wessels MR, Paoletti LC, Pinel J, Kasper DL (1995) Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J. Infect. Dis. 171:879-884.
62. Baker CJ, Paoletti LC, Rench MA, Guttormsen H-K, Edwards MS, Kasper DL (2004) Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines. J. Infect. Dis. 189:1103-1112.
63. Gravekamp C, Kasper DL, Paoletti LC, Madoff LC (1999) Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines. Infect. Immun. 67:2491-2496.
64. Paoletti LC, Peterson DL, Legmann R, Collier RJ (2002) Preclinical evaluation of group B streptococcal polysaccharide conjugate vaccines prepared with a modified diphtheria toxin and a recombinant duck hepatitis B core antigen. Vaccine 20:370-376.
65. Wessels MR, Munoz A, Kasper DL (1987) A model of high-affinity antibody binding to type III group B Streptococcus capsular polysaccharide. Proc. Natl. Acad. Sci. U.S.A. 84:9170-9174.
66. Michon F, Uitz C, Tai JY (2002) Antigenic group B Streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof. U.S. Patent 6,372222.
67. Michon F, Uitz C, Tai JY (2003) Method of immunization using a group B Streptococcus type II and type III polysaccharide conjugate vaccine. U.S. Patent 6,602508.
68. Zou W, Laferriere CA, Jennings HJ (1998) Oligosaccharide fragments of the type III group B streptococcal polysaccharide derived from S. pneumoniae type 14 capsular polysaccharide by a chemoenzymatic method. Carbohydr. Res. 309:297-301.
69. Wang Y, Hollingsworth RI, Kasper DL (2001) Method for generating antibodies to saccharide fragments. U.S. Patent 6,274144.
70. Wang Y, Hollingsworth RI, Kasper DL (1998) Ozonolysis for selectively depolymerizing polysaccharides containing ß-aldosidic linkages. Proc. Natl. Acad. Sci. U.S.A. 95:6584-6589.
71. Wang JY, Chang AHC, Guttormsen H-K, Rosas AL, Kasper DL (2003) Construction of designer glycoconjugate vaccines with size-specific oligosaccharide antigens and site-controlled coupling. Vaccine 21:1112-1117.
72. Moreau M, Richards JC, Fournier JM, Bryla DA, Karakawa WW, Vann WF (1990) Structure of the type 5 capsular polysaccharide of Staphylococcus aureus. Carbohydr. Res. 201:285-297.
73. Fournier JM, Vann WF, Karakawa WW (1984) Purification and characterization of Staphylococcus aureus type 8 capsular polysaccharide. Infect. Immun. 45:87-93.
74. Fattom A, Shiloach J, Bryla D, Fitzgerald D, Pastan I, Karakawa WW, Robbins JB, Schneerson R (1992) Comparative immunogenicity of conjugates composed of the Staphylococcus aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or N-succinimidyl-3-(2-pyridyldithio)propionate. Infect. Immun. 60:584-589.
75. Fattom A, Schneerson R, Watson DC, Karakawa WW, Fitzgerald D, Pastan I, Li X, Shiloach J, Bryla DA, Robbins JB (1993) Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect. Immun. 61: 1023-1032.
76. Robbins JB, Chu CY, Schneerson R (1992) Hypothesis for vaccine development: Protective immunity to entric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides. Clin. Infect. Dis. 15:346-361.
77. Cryz SJ, Furer EP (1994) Escherichia coli O-polysaccharide-protein conjugate vaccine. U.S. Patent 5,370872.
78. Konadu E, Robbins JB, Shiloach J, Bryla DA, Szu SC (1994) Preparation, characterization, and immunological properties in mice of Escherichia coli O157 O-specific polysaccharide-protein conjugate vaccines. Infect. Immun. 62:5048-5054.
79. Konadu E, Donohue-Rolfe A, Calderwood SB, Pozsgay V, Shiloach J, Robbins JB, Szu SC (1999) Syntheses and immunologic properties of Escherichia coli O157 O-specific polysaccharide and shiga toxin 1 B subunit conjugates in mice. Infect. Immun. 67:6191-6193.
80. Lees A, Nelson BL, Mond JJ (1995) Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents. Vaccine 14:190-198.
81. Konadu EY, Parke JC, Tran HT, Bryla DA, Robbins JB, Szu SC (1998) Investigational vaccine for Escherichia coli O157: Phase I study of O157 O-specific polysaccharide Pseudomonas aeruginosa recombinant exoprotein A conjugates in adults. J. Infect. Dis. 177:383-387.
82. Jin Z, Chu C, Robbins JB, Schneerson R (2003) Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice. Infect. Immun. 71:5115-5120.
83. Gupta RK, Szu SC, Finkelstein RA, Robbins JB (1992) Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin. Infect. Immun. 60:3201-3208.
84. Gupta RK, Taylor DN, Bryla DA, Robbins JB, Szu SSC (1998) Phase 1 evaluation of Vibrio cholerae O1, serotype Inaba, polysaccharide-cholera toxin conjugates in adult volunteers. Infect. Immun. 66:3095-3099.
85. Boutonnier A, Villeneuve S, Nato F, Dassy B, Fournier JM (2001) Preparation, immunogenicity, and protective efficacy, in a murine model, of a conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid. Infect. Immun. 69:3488-3493.
86. Kossaczka Z, Shiloach J, Johnson V, Taylor DN, Finkelstein RA, Robbins JB, Szu SC (2000) Vibrio cholerae O139 conjugate vaccines: Synthesis and immunogenicity of V. cholerae O139 capsular polysaccharide conjugates with recombinant diphtheria toxin mutant in mice. Infect. Immun. 68:5037-5043.
87. Chu CY, Liu BK, Watson D, Szu SC, Bryla D, Shiloach J, Schneerson R, Robbins JB (1991) Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid. Infect. Immun. 59:4450-4458.
88. Ashkenazi S, Passwell JH, Harlev E, Miron D, Dagan D, Farzan N, Ramon R, Majadly F, Bryla DA, Karpas AB, Robbins JB, Schneerson R, the Israel Pediatric Shigella Study Group (1999) Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children. J. Infect. Dis. 179:1565-1568.
89. Pavliakova D, Chu C, Bystricky S, Tolson NW, Shiloach J, Kaufman JB, Bryla DA, Robbins JB, Schneerson R (1999) Treatment with succinic anhydride improves the immunogenicity of Shigella flexneri type 2a O-specific polysaccharide-protein conjugates in mice. Infect. Immun. 67:5526-5529.
90. Passwell JH, Ashkenazi S, Harlev E, Miron D, Ramon R, Farzam N, Lerner GL, Levi Y, Chu CY, Shiloach J, Robbins JB, Schneerson R (2003) Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPA(succ) conjugate vaccines in one-to four-year-old children. Pediat. Infect. Dis. J. 22:701-706.
91. Jennings HJ, Lugowski C, Ashton FE (1984) Conjugation of meningococcal lipopolysaccharide R-type oligosaccharides to tetanus toxoid as route to a potential vaccine against group B Neisseria meningitidis. Infect. Immun. 43:407-412.
92. Grimmecke HD, Brade H (1998) Studies on the reductive amination of 3-deoxy-D-mannooctulosonic acid (Kdo). Glyconjugate J. 15:555-562.
93. Verheul AF, Braat AK, Leenhouts JM, Hoogerhout P, Poolman JT, Snippe H, Verhoef J (1991) Preparation, characterization, and immunogenicity of meningococcal immunotype L2 and L3,7,9-phosphoethanolamine group-containing oligosaccharide-protein conjugates. Infect. Immun. 59:843-851.
94. Gu XX, Tai CM (1993) Preparation, characterization, and immunogenicity of meningococcal lipooligosaccharide-derived oligosaccharide-protein conjugates. Infect. Immun. 61:1873-1880.
95. Gu XX, Chen J, Barenkamp SJ, Robbins JB, Tsai CM, Lim DJ, Battey J (1998) Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis. Infect. Immun. 66:1891-1897.
96. Gu XX, Tsai CM, Ueyama T, Barenkamp SJ, Robbins JB, Lim DJ (1996) Synthesis, characterization, and immunologic properties of detoxified lipooligosaccharide from nontypeable Haemophilus influenzae conjugated to proteins. Infect. Immun. 64:4047-4053.
97. Gu XX, Tai CM, Lim DJ, Robbins JB (2001) Conjugate vaccine for nontypeable Haemophilus influenzae. U.S. Patent 6,207157.
98. Gu XX, Rudy SE, Chu CY, McCullagh L, Kim HN, Chen J, Li JP, Robbins JB, VanWaes C, Battey JE (2003) Phase I of a lipooligosaccaride-based conjugate vaccine against nontypeable Haemophilus influenzae. Vaccine 21:2107-2114.
99. Gu XX, Tsai CM, Lim DJ, Robbins JB (2003) Conjugate vaccine for nontypeable Haemophilus influenzae. U.S. Patent 6,607725.
100. Gu XX, Tai CM (2003) Conjugate vaccine for Neisseria meningitidis. U.S. Patent 6,531131.
101. Yu S, Gu XX (2005) Synthesis and characterization of lipooligosaccharide-based conjugate vaccines for serotype B Moraxella catarrhalis. Infect. Immun. 73:2790-2796.
102. Yu S, Gu XX (2007) Biological and immunological characteristics of lipooligosaccharide-based conjugate vaccines for serotype C Moraxella catarrhalis. Infect. Immun. 75:2974-2980.
103. Cox AD, ZouW, Gidney MAJ, Lacelle S, Plested JS, Makepeace K,Wright JC, Coull PA, Moxon ER, Richards JC (2005) Candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: Developmental chemistry and investigation of immunological responses following immunization of mice and rabbits. Vaccine 23:5045-5054.
104. Müller-Loennies S, Grimmecke D, Brade L, Lindner B, Kosma P, Brade H (2002) A novel strategy for the synthesis of neoglycoconjugates from deacylated deep rough lipopolysaccharides. J. Endotoxin Res. 8:295-305.
105. Mieszala M, Kogan G, Jennings HJ (2003) Conjugation of meningococcal lipooligosaccharides through their lipid A terminus conserves their inner epitopes and results in conjugate vaccines having improved immunological properties. Carbohydr. Res. 338:167-175.
106. Verez-Bencomo V, Fernandez-Santana V, Hardy E, Toledo ME, Rodriguez MC, Heynngnezz L, Rodriguez A, Baly A, Herrera L, Izquierdo M, Villar A, Valdes Y, Cosme K, Deler ML, Montane M, Garcia E, Ramos A, Aguilar A, Medina E, Torano G, Sosa I, Hernandez I, Martinez R, Muzachio A, Carmenates A, Costa L, Cardoso F, Campa C, Diaz M, Roy R (2004) A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science 305:522-525.
107. Fernandez-Santana V, Cardoso F, Rodriguez A, Carmenate T, Pena L, Valdes Y, Hardy E, Mawas F, Heynngnezz L, Rodriguez MC, Figueroa I, Chang J, Toledo ME, Musacchio A, Hernandez I, Izquierdo M, Cosme K, Roy R, Verez-Bencomo V (2004) Antigenicity and immunogenicity of a synthetic oligosaccharide-protein conjugate vaccine against Haemophilus influenzae type b. Infect. Immun. 72:7115-7123.
108. Peeters CC, Evenberg D, Hoogerhout P, Käyhty H, Saarinen L, Van Boeckel CA, van der Marel GA, Van Boom JH, Poolman JT (1992) Synthetic trimer and tetramer of 3-beta-Dribose-( 1-1)-D-ribitol-5-phosphate conjugated to protein induce antibody responses to Haemophilus influenzae type b capsular polysaccharide in mice and monkeys. Infect. Immun. 60:1826-1833.
109. Lefeber DJ, Kamerling JP, Vliegenthart JFG (2001) Synthesis of Streptococcus pneumoniae type 3 neoglycoproteins varying in oligosaccharide chain length, loading and carrier protein. Chem. Eur. J. 7:4411-4421.
110. Benaissa-Trouw B, Lefeber DJ, Kamerling JP, Vliegenthart JFG, Kraaijeveld K, Snippe H (2001) Synthetic polysaccharide type 3-related di-, tri-, and tetrasaccharide-CRM197 conjugates induce protection against Streptococcus pneumoniae type 3 in mice. Infect. Immun. 69:4698-4701.
111. Lefeber DJ, Benaissa TB, Vliegenthart JFG, Kamerling JP, Jansen WTM, Kraaijeveld K, Snippe H (2003) Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3. Infect. Immun. 71:6915-6920.
112. Jansen WTM, Hogenboom S, Thijssen MJ, Kamerling JP, Vliegenthart JFG, Verhoef J, Snippe H,Verheul AF (2001) Synthetic 6B di-, tri-, and tetrasaccharide-protein conjugates contain pneumococcal type 6a and 6b common and 6B-specific epitopes that elicit protective antibodies in mice. Infect. Immun. 69:787-793.
113. Alonso De Velasco E, Verheul AF, Veeneman GH, Gomes LJF, Van Boom JH, Verhoef J, Snippe H (1993) Protein-conjugated synthetic di-and trisaccharides of pneumococcal type 17F exhibit a different immunogenicity and antigenicity than tetrasaccharide. Vaccine 11:1429-1436.
114. Alonso De Velasco E, Verheul AF, Van Steijn AMP, Dekker HAT, Feldman RG, Fernandez IM, Kamerling JP, Vliegenthart JFG, Verhoef J, Snippe H (1994) Epitope specificity of rabbit immunoglobulin G (IgG) elicited by pneumococcal type 23F synthetic oligosaccharide-and native polysaccharide-protein conjugate vaccines: Comparison with human anti-polysaccharide 23F IgG. Infect. Immun. 62:799-808.
115. Lee RT, Lee YC (1974) Synthesis of 3-(2-aminoethylthio)propyl glycosides. Carbohydr. Res. 37:193-201.
116. Mawas F, Niggemann J, Jones C, Corbel MJ, Kamerling JP, Vliegenthart JFG (2002) Immunogenicity in a mouse model of a conjugate vaccine made with a synthetic single repeating unit of type 14 pneumococcal polysaccharide coupled to CRM197. Infect. Immun. 70:5107-5114.
117. Chernyak A, Karavanov A, Ogawa Y, Kovac P (2007) Conjugating oligosaccharides to proteins by squaric acid diester chemistry: Rapid monitoring of the progress of conjugation, and recovery of the unused ligand. Carbohydr. Res. 330:479-486.
118. Chernyak A, Kondo S,Wade TK, Meeks MD, Alzari PM, Fournier JM, Taylor RK, Kovac P, Wade WF (2002) Induction of protective immunity by synthetic Vibrio cholerae hexasaccharide derived from V. cholerae O1 Ogawa lipopolysaccharide bound to a protein carrier. J. Infect. Dis. 185:950-962.
119. Meeks MD, Saksena R, Ma XQ, Wade TK, Taylor RK, Kovac P, Wade WF (2004) Synthetic fragments of Vibrio cholerae O1 Inaba O-specific polysaccharide bound to a protein carrier are immunogenic in mice but do not induce protective antibodies. Infect. Immun. 72:4090-4101.
120. Pozsgay V (1998) Synthetic Shigella vaccines: A carbohydrate-protein conjugate with totally synthetic hexadecasaccharide haptens. Angew. Chem. Inter. Ed. Eng. 37:138-142.
121. Pozsgay V, Chu C, Pannell L, Wolfe J, Robbins JB, Schneerson R (1999) Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1. Proc. Natl. Acad. Sci. USA 96:5194-5197.
122. Pozsgay V, Vieira NE, Yergey A (2002) A method for bioconjugation of carbohydrates using Diels-Alder cycloaddition. Org. Lett. 4:3191-3194.
123. Pozsgay V (2007) Conjugation of biomolecules using Diels-Alder cycloaddition. U.S. Patent 7211445.